Abstracts tagged "Ankylosing spondylitis (AS)"

Abstract Number: 0224 • ACR Convergence 2024
How Accurate Are Assessments by Local Radiologists of Sacroiliac Joint MRIs in Axial Spondyloarthritis and Psoriatic Arthritis in Routine Clinical Practice?- Evidence from 873 Patients in Five European Countries
Anna EF Hadsbjerg¹, Simon Krabbe², Nora Vladimirova², Adrian Ciurea³, Kristyna Bubova⁴, Monika Gregová⁴, Michael Nissen⁵, Burkhard Moeller⁶, Raphael Micheroli⁷, Susanne Pedersen⁸, Jakub Zavada⁴, Ziga Snoj⁹, Karlo Pintaric⁹, Bjorn Gudbjornsson¹⁰, Ziga Rotar¹¹, iris Eshed¹², Iwona Sudol-Szopinska¹³, Kasper Gosvig¹⁴, Torsten Diekhoff¹⁵, Robert Lambert¹⁶, Manouk de hOoge¹⁷, Helena V G Elmo¹, Merete Hetland¹⁸, Lykke Oernbjerg¹⁹ and Mikkel Ostergaard²⁰, ¹Copenhagen Center for Arthritis Research, Center for Rheumatology and Spine Diseases, Centre for Head and Orthopaedics, Righospitalet, Glostrup, Denmark, ²Copenhagen Center for Arthritis Research, Center for Rheumatology and Spine Diseases, Centre for Head and Orthopaedics, Righospitalet, Copenhagen, Denmark, ³University Hospital Zurich, Zürich, Switzerland, ⁴Institute of Rheumatology and Department of Rheumatology, First Faculty of Medicine Charles University, Prague, Czech Republic, ⁵Geneva University Hospital, Geneva, Switzerland, ⁶Inselspital - University Hospital Bern, Bern, Switzerland, ⁷University Hospital Zurich, Zurich, Switzerland, ⁸Rigshospitalet, København, Denmark, ⁹Institute of Radiology, UMC Ljubljana, Ljubljana, Slovenia, ¹⁰Landspitali University Hospital and University of Iceland, Reykjavik, Iceland, ¹¹University Medical Centre Ljubljana and University of Ljubljana, Ljubljana, Slovenia, ¹²Sheba Medical Center, Tel Hashomer affiliated with School of medicine, Tel Aviv University, Department of Diagnostic Imaging, Tel Aviv, Israel, ¹³Department of Radiology, National Institute of Geriatrics, Rheumatology and Rehabilitation, Warsaw, Poland, ¹⁴Department of Radiology, Copenhagen University Hospital Herlev-Gentofte, Herlev, Denmark, ¹⁵Charite Universitatsmedizin Berlin, Berlin, Germany, ¹⁶University of Alberta, Edmonton, AB, Canada, ¹⁷Dept. of Internal Medicine and Pediatrics, Ghent University, Ghent, Belgium, ¹⁸Rigshospitalet Glostrup and University of Copenhagen, Glostrup, Denmark, ¹⁹Rigshospitalet Glostrup, Glostrup, Hovedstaden, Denmark, ²⁰Department of Clinical Medicine, University of Copenhagen and Center for Rheumatology, Copenhagen Center for Arthritis Research, Glostrup, Denmark
Background/Purpose: MRI of the sacroiliac joints (SIJs) is widely used for diagnosing and monitoring patients with spondyloarthritis (SpA). However, local radiologists might be less familiar with…
Abstract Number: 0573 • ACR Convergence 2024
Characteristics of Difficult-to-Treat Ankylosing Spondylitis- Results from Real-World Data
Ansaam Daoud¹, Jennifer Murphy², Omer Pamuk³ and Marina Magrey⁴, ¹Case Western Reserve University/University Hospitals, Akron, OH, ²University Hospitals, Cleveland, OH, ³University Hospitals Cleveland Medical Center/ Case Western Reserve University, Cleveland, OH, ⁴Case Western Reserve University School of Medicine/University Hospitals, Richfield, OH
Background/Purpose: A large proportion of patients with ankylosing spondylitis (AS) are considered difficult to treat (D2T).The study aimed to compare baseline characteristics, extra-articular manifestations (EAM),…
Abstract Number: 1249 • ACR Convergence 2024
Patient-Reported Outcomes in Inflammatory Arthritis: A Four-Year Retrospective Analysis via the PatientSpot Research Registry
Shilpa Venkatachalam¹, Kelly Gavigan², Erik Stone³, Angela Degrassi², Laura Stradford⁴, David Curtis², Esteban Rivera⁵ and Jeffrey Curtis⁶, ¹Global Healthy Living Foundation, New York, NY, ²Global Healthy Living Foundation, Upper Nyack, NY, ³Global Healthy Living Foundation, Upper Nyack, ⁴Global Healthy Living Foundation, Nyack, NY, ⁵Global Healthy Living Foundation, Long Island City, NY, ⁶University of Alabama at Birmingham, Hoover, AL
Background/Purpose: Understanding the impact of inflammatory arthritis from patients’ perspectives through patient-reported outcomes (PROs) data can provide valuable insights into outcomes prioritized by those living…
Abstract Number: 1480 • ACR Convergence 2024
Sustained Improvements with Bimekizumab in Spinal Mobility, Physical Function and Health-Related Quality of Life in Patients with Axial Spondyloarthritis: 2-Year Results from Two Phase 3 Studies
Victoria Navarro Compán¹, Maureen Dubreuil², Karl Gaffney³, Jonathan Kay⁴, Christine de la Loge⁵, Ute Massow⁶, Vanessa Taieb⁷, Thomas Vaux⁸ and Atul Deodhar⁹, ¹La Paz University Hospital, Hospital La Paz Institute for Health Research (IdiPAZ), Madrid, Spain, ²Section of Rheumatology, Boston University School of Medicine, Boston, MA, ³Health Care - NHS, Norwich, United Kingdom, ⁴Division of Rheumatology, Department of Medicine, UMass Chan Medical School and UMass Memorial Medical Center, Worcester, MA, ⁵UCB Pharma, Brussels, Belgium, ⁶UCB Pharma, Monheim am Rhein, Germany, ⁷UCB Pharma, Colombes, France, ⁸UCB Pharma, Slough, United Kingdom, ⁹Division of Arthritis and Rheumatic Diseases, Oregon Health & Science University, Portland, OR
Background/Purpose: In the phase 3 BE MOBILE 1 and 2 studies, bimekizumab (BKZ), a monoclonal IgG1 antibody that inhibits interleukin (IL)-17F in addition to IL-17A,…
Abstract Number: 2278 • ACR Convergence 2024
Similar Etanercept Adherence in Individuals with Rheumatic Disease Initiating Originator and Biosimilar: A Population-Based Study
Olga Tsyruk¹, Marina Birck², Sasha Bernatsky², Luck Lukusa³, Denis Choquette⁴, Gilles Boire⁵ and Walter Maksymowych⁶, ¹McGill University, Montreal, QC, Canada, ²Research Institute of the McGill University Health Centre, Montreal, QC, Canada, ³The Research Institute of the McGill University Health Centre, Montreal, QC, Canada, ⁴Rhumadata™, Montreal, QC, Canada, ⁵Retired, Sherbrooke, QC, Canada, ⁶University of Alberta, Edmonton, AB, Canada
Background/Purpose: Treatment adherence is crucial to optimizing outcomes in rheumatic diseases. Suboptimal adherence is common with inflammatory and chronic diseases, often treated with biologics, including…
Abstract Number: 0231 • ACR Convergence 2024
Imaging Characteristics and Demographic Variations in Patients with Axial Spondylarthritis, Axial Psoriatic Arthritis, and Inflammatory Bowel Disease-Related Arthritis with Axial Involvement: Insights from a Single Center at Cleveland Clinic Abu Dhabi
Rajaie Namas¹, Ahlam Almarzooqi², Sarah Al Qassimi³ and Esat Memisoglu³, ¹Cleveland Clinic Abu Dhabi, Detroit, MI, ²Emirates Health Services, Sharjah, United Arab Emirates, ³Cleveland Clinic Abu Dhabi, Abu Dhabi, United Arab Emirates
Background/Purpose: Spondyloarthropathies (SpAs) are a group of seronegative, inflammatory arthritides, including axial spondylarthritis (ax-SpA), axial psoriatic arthritis (ax-PsA), and inflammatory bowel disease related arthritis with…
Abstract Number: 0574 • ACR Convergence 2024
14-3-3 Eta (η) Auto-Antibody as a Diagnostic Marker in Axial Spondyloarthritis: A Longitudinal Study
Anthony Marotta¹, Walter Maksymowych², Stephanie Wichuk² and Navneet Sidhu¹, ¹Augurex Life Sciences Corp, Vancouver, BC, Canada, ²University of Alberta, Edmonton, AB, Canada
Background/Purpose: Diagnosis of axial spondyloarthritis (AxSpA) is challenging and often delayed primarily due to the lack of sensitive and specific markers needed for accurate and…
Abstract Number: 1251 • ACR Convergence 2024
Current Disease Management and Treatment Satisfaction in Axial Spondyloarthritis (axSpA) in Europe: Patient and Rheumatologist Perspectives
Xenofon Baraliakos¹, Victoria Navarro Compán², Elena Nikiphorou³, Thao Pham⁴, Francesco Ciccia⁵, Megan Hughes⁶, Bruno Kranz⁶, Anna Jus⁷, Chris Watson⁷, Jo Lowe⁸ and Sofia Ramiro⁹, ¹Rheumazentrum Ruhrgebiet Herne, and Ruhr-University Bochum, Bochum, Germany, ²La Paz University Hospital, Hospital La Paz Institute for Health Research (IdiPAZ), Madrid, Spain, ³King's College London, London, United Kingdom, ⁴Assistance Publique-Hôpitaux de Marseille, Marseille, France, ⁵Università degli studi della Campania Luigi Vanvitelli, Naples, Italy, ⁶Adelphi Real World, Bollington, United Kingdom, ⁷Alfasigma S.p.A., Bologna, Italy, ⁸Axial Spondyloarthritis International Federation, London, United Kingdom, ⁹Leiden University Medical Center, Bunde, Netherlands
Background/Purpose: A survey was conducted to better understand the characteristics and management of axSpA and patient and physician perspectives on current treatment.Methods: In March 2024,…
Abstract Number: 1482 • ACR Convergence 2024
Predictors of Clinical Response to Intravenous Secukinumab Among Patients with Axial Spondyloarthritis: A Post Hoc Analysis of a Phase 3 Trial
Atul Deodhar¹, Eva Dokoupilova², Cynthia Vizcaya³, Reema Sutariya⁴, Weibin Bao⁴, Karen Kapur³, Susanne Rohrer³ and Alan Kivitz⁵, ¹Division of Arthritis and Rheumatic Diseases, Oregon Health & Science University, Portland, OR, ²Medical Plus, s.r.o., Uherske Hradiste, and Masaryk University, Faculty of Pharmacy, Department of Pharmaceutical Technology, Prague, Czech Republic, ³Novartis Pharma AG, Basel, Switzerland, ⁴Novartis Pharmaceuticals Corporation, East Hanover, NJ, ⁵Altoona Center for Clinical Research, Duncansville, PA

Background/Purpose: This post hoc analysis of the INVIGORATE-1 study evaluated potential predictors of Ankylosing Spondylitis international Society (ASAS) 40 response in patients with axial spondyloarthritis…
Abstract Number: 2344 • ACR Convergence 2024
Secukinumab Retention and Effectiveness in Patients with Psoriatic Arthritis and Radiographic Axial Spondyloarthritis: 5-year Final Results of a Prospective Real-world Study
Uta Kiltz¹, Petros Sfikakis², Andreas Bounas³, Nicola Gullick⁴, Eric LESPESSAILLES⁵, Jan Brandt Jürgens⁶, Rasho Rashkov⁷, Barbara Schulz⁸, Weibin Bao⁹, Piotr Jagiello¹⁰ and Karl Gaffney¹¹, ¹Rheumazentrum Ruhrgebiet Herne, Ruhr-University, D-44649 Herne, Germany, ²Joint Academic Rheumatology Program, School of Medicine, National and Kapodistrian University of Athens. Centre of New Biotechnologies and Precision Medicine (CNBPM), School of Medicine, National and Kapodistrian University of Athens, Athens, Greece, Athens, Greece, ³PRIVATE PRACTICE, Patra, Greece, ⁴Rheumatology Department, University Hospitals Coventry and Warwickshire NHS Trust, Coventry, Coventry, United Kingdom, ⁵CHR ORLEANS, ORLEANS, France, ⁶Rheumatologische Schwerpunktpraxis, Berlin, Germany, ⁷Clinic of Rheumatology, University Hospital St. Ivan Rilski, Sofia, Bulgaria, ⁸GKM Gesellschaft für Therapieforschung mbH, Lessingstrasse, Munchen, Germany, ⁹Novartis Pharmaceuticals Corporation, East Hanover, NJ, ¹⁰Novartis Pharma AG, Basel, Switzerland, Basel, Switzerland, ¹¹Health Care - NHS, Norwich, United Kingdom
Background/Purpose: Real-world data on long-term use of secukinumab complements clinical trial findings by providing insights from diverse patients in routine clinical settings. SERENA (CAIN457A3403) was…
Abstract Number: 0352 • ACR Convergence 2024
Fast-tracking Axial Spondyloarthritis Diagnosis: A Novel Approach to Public Health Advocacy and Awareness
Joe Eddison, National Axial Spondyloarthritis Society, London, United Kingdom
Background/Purpose: The Act on Axial SpA campaign is dedicated to minimising the lengthy 8.5-year delay in diagnosing axial spondyloarthritis (axial SpA) by implementing a pioneering…
Abstract Number: 0578 • ACR Convergence 2024
Gender Differences in Disease Parameters, Adherence to Treat to Target Strategy and Outcomes in Axial Spondyloarthritis (axSpA) in Pakistani Cohort
Muhammad Saeed¹, HIna Ahmed² and Aziza Ahmed³, and Arthritis Carte Foundation Faculty, ¹Central Park Medical College, Arthritis Care Foundation, Lahore, Pakistan, ²Central Park Medical College, Lahore, Pakistan, ³Rashid Latif Medical College, Lahore, Pakistan
Background/Purpose: In patients with Axial Spondyloarthritis (axSpA) there has been wide variability in terms of gender regarding disease characteristics as well as outcomes across different…
Abstract Number: 1296 • ACR Convergence 2024
Effectiveness of Inflammatory Arthritides Educational Modules and Potential for Improved Referral Times
Christine Kim¹, Vincent Vertalino², Karen Kruzer³ and Allen Anandarajah⁴, ¹University of Rochester, Rochester, ²University of Rochester, Hamburg, NY, ³University of Rochester, Victor, NY, ⁴University of Rochester Medical Center, Rochester, NY
Background/Purpose: Early diagnosis and treatment of inflammatory arthritides [rheumatoid arthritis (RA), psoriatic arthritis (PsA) and ankylosing spondylitis (AS)] are associated with improved patient outcomes. However,…
Abstract Number: 1707 • ACR Convergence 2024
TRBV9-Targeted Bispecific T Cell-Engaging Antibodies to Reset the Autoreactive T Cell Compartment in Spondyloarthritis and HLA-DQ8 Celiac Disease
Stephanie Glavaris, Alexander Pearlman, Jin Liu, Jiaxin Ge, Yuanxuan Xia, Kyle J. Kaeo, Tolulope Awosika, Colin Gliech, Tushar Nichakawade, Nikita Marcou, Chetan Bettegowda, Drew Pardoll, Kenneth W. Kinzler, Shibin Zhou, Bert Vogelstein, Suman Paul and Maximilian F. Konig, The Johns Hopkins University School of Medicine, Baltimore, MD
Background/Purpose: Therapies that indiscriminately deplete all T cells carry a high risk of opportunistic infection, precluding their widespread use in T cell-mediated autoimmune diseases. Targeting…
Abstract Number: 2346 • ACR Convergence 2024
Treatment Effect on Predictors of Ankylosis in Axial Spondyloarthritis
Pauline KRUG¹, Anthony Lichaa¹ and Adrien Nzeusseu Toukap², ¹Cliniques universitaires St-Luc, Brussel, Belgium, ²Cliniques universitaires Saint-Luc,, St.-Lambrechts-Woluwe, Belgium
Background/Purpose: Axial spondyloarthritis (axSpA) is a progressive chronic inflammatory disease. In its early stages, symptoms appear without radiographic evidence. Later, structural lesions are observed on…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].